Driving to a Cure
Andrew Lee ’18 was diagnosed with a rare and incurable
cancer. He turned it into a cause.
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LAST FALL, when medical tests revealed that Dawn Cockrum’s 8-year-old daughter,
Lily, was at high risk for a rare disease called hereditary leiomyomatosis and renal cell
cancer (HLRCC), the Winston-Salem, North Carolina, resident reached out to Bruce
Lee in Kensington, Maryland. Lily’s local doctors had never before encountered
HLRCC, had no idea how to treat it — and weren’t quite sure how to connect the
Cockrums with Maryland’s National Institutes of Health, the closest center with
specialists for the disease.

Lee isn’t one of those specialists, however. He’s the father of the late Andrew Lee ’18,
who received an HLRCC diagnosis in May 2015, at the end of his fresh- man year at
UNH. Initially given six months to a year to live, Andrew had a heart-to-heart with his
father, who asked him what his life goals were, given that his time was limited.
“Andrew told me he’d love to have a great job like mine so he could buy his dream car,
a Nissan GT-R,” Lee recalls. “I asked him, ‘a GT-R? what’s that?’”

Lee soon found out. He deliberated for less than a day before deciding to buy his son
the luxury sports car, which attracted attention wherever Andrew went, and it wasn’t
long before Andrew realized his new vehicle could be a vehicle — to raise awareness
about and money to support research for HLRCC. When Andrew died on April 21, 2019,
nearly four years after his diagnosis, his dream car had become the basis of a nonprofit
organization, Driven To Cure (DTC), that has raised more than $600,000 for research
on HLRCC and other rare kidney cancers and become a source of information about
the disease for individuals and families.
“When Dawn Cockrum reached out to me, one of the first things she said was, ‘any time
you search online for HLRCC, the first thing that comes up is Driven To Cure,’” Lee
explains.
And that’s only the beginning of the legacy of Andrew Lee.
“Let’s find a cure”
Andrew grew up in the D.C. suburb of Kensington, the least-memorably named member
of a family that includes not only father Bruce but also mother Sarah and brother
Tommy. An avid soccer player and golfer, Andrew had always figured he’d head south
for college, but he was “intrigued” by UNH’s location — an easy drive to ski mountains
and to the ocean, two destinations he particularly loved — as well as the strength of the
Peter T. Paul College of Business and Economics.
“He liked the fact that at UNH, you could jump into business courses right away,” Lee
recalls.

The head of a family-owned real estate development company, Lee says that Andrew, a
business administration major, had planned to come work with him after college and
eventually own and operate his own real estate brokerage firm, and to that end Andrew
had spent his freshman spring break registering for summer real estate licensing
courses. That plan went out the window when the excruciating abdominal pain Lee
found his son in the day he came to collect Andrew from UNH turned out to be not
appendicitis, as initially suspected, but internal bleeding, caused by a cancerous tumor
that had eroded through his kidney wall. He was quickly transferred from WentworthDouglass Hospital in Dover to Boston’s Massachusetts General Hospital, where David
Sweetser, MD, the chief of medical genet- ics, made the devastating diagnosis of
HLRCC.
“Dr. Sweetser told us, ‘I think I know what this is, and I think it’s really bad,’” Lee says.
“Andrew had about 20 minutes of ‘why me?’ but then it was like a faucet turning off.
After that, it was just, ‘Dad, let’s beat this. Let’s find a cure.’”
HLRCC falls under the heading of rare genetic disorders. Caused by a mutation in one
copy of the fumarate hydratase (FH) gene — everyone has two — it typically manifests
as benign smooth muscle tissue tumors (leiomyomas) that can appear anywhere on the
body; in only approximately 0.1 percent of cases does HLRCC develop into cancerous
kidney tumors. According to the U.S. National Library of Medicine, HLRCC cancer is so
rare, it’s only been diagnosed in about 100 families worldwide. When Andrew’s was
diagnosed at Mass General in late May 2015, both of his kidneys were already riddled
with cancer and there was a tumor in his pelvic bone. He was considered stage 4, the
most advanced.

LEE BRINGING A SMILE TO A
FELLOW PATIENT AT THE CHILDREN’S INN AT NIH.
As of now, HLRCC has no known cure, but Mass General’s Sweetser knew that the
National Institutes of Health (NIH) was the one place in the United States that was
having success stabilizing patients and limit- ing the spread of their cancer. It also
happened to be in the Lees’ back yard, and within short order Andrew was enrolled in a
clinical trial that kept him stable for nearly 18 months — far longer than he’d originally
been told he would survive. He got his GT-R, and he returned to UNH to complete the
first semester of his sophomore year, flying home to Maryland every other weekend for
treatment.
The side effects of the treatment were challenging, however, and after a semester of
juggling treatments and a full schedule of business management courses, Andrew
realized he needed to take a different approach. He’d already begun taking his GT-R to
car shows, where the reason for his owning it inevitably came up, and the idea of
turning the car into a nonprofit to raise money and awareness started to take hold. He
came up with the name and a slogan — “Built to drive, driven to cure” — secured the
Driven To Cure domain name for $7.99, and in January 2016 approached Paul College
professor Andrew Earle about enrolling in what was then an experimental course for
entrepreneur- ship-minded students, “Launching New Ventures,” to formalize his
fundraising efforts.

ANDREW AT NIH WITH HIS
GIRLFRIEND, HAILEY KELLOGG ’18, AND THEIR FRENCH BULLDOG, MILO.
With Earle’s guidance, Andrew developed a formal business plan, built the Driven To
Cure website, designed logos, branding and social media, created a board of directors
and filed the paperwork to incorporate as a 501(c)3 nonprofit. By that April, Driven To
Cure was officially open for business, selling merchandise (T-shirts, sweatshirts and
hoodies, wristbands, decals and stickers) emblazoned with the DTC logo. With average
donations in the $50 range, the organization raised a remarkable $200,000 its first year,
which Andrew donated to NIH. There, it supports the work of W. Marston Linehan, MD,
chief of urologic surgery and urologic oncology, who pioneered the study of the genetic
basis of kidney cancer and is developing new approaches to treat multiple forms of the
disease.
Finding meaning
From the start, Andrew knew that his cancer was incurable, but he found purpose and
meaning in making a difference for others. To that end, he enrolled in some seven
clinical trials through the NIH, Yale University’s Smilow Cancer Center and
Georgetown’s Lombardi Cancer Center. He and his family also felt strongly that all of
the money raised by DTC go toward research, even when the trial protocols he was on
stopped work- ing and they needed to pursue avenues of treatment not covered by
insurance — to the tune of multiple thousands of dollars a month.
“It’s a question that’s come up before,” Lee acknowledges. “Why didn’t you use the
proceeds from Driven To Cure to pay for Andrew’s treatments?” Lee says that Andrew
understood he came from a privileged background, and that his family could find ways
to cover his treatments, even if those ways were financially burden- some. “He knew
there were other people out there for which that simply wasn’t an option. His goal was
always to help others.”
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That help took a wide variety of forms, including sharing his GT-R, painted a custom
orange for kidney cancer, with as many people as possible. He frequently brought the
car to the Children’s Inn at NIH — the residential facility where patients stay with their
parents while undergoing treatment in clinical trials — to take his fellow patients
joyriding. Among those with whom he became close was 15-year-old Isaac Barchus of
Omaha, Nebraska, who suffers from a rare autoinflammatory disease for which he
receives treatment at NIH. Not only did Isaac and Andrew bond over long rides and
conversations in Andrew’s GT-R, when Andrew’s cancer progressed to the point he
required a wheelchair to get around, he chose a model that would work for Isaac, too,
knowing he’d only be using it for a limited time. Last June, less than two months after
Andrew’s death, Lee delivered the chair to the Barchus family, refurbished with DTC
orange paint and emblazoned with a replica of the GT-R’s thumb-to-the-nose FCANCR
license plate. In 2017, the state of Maryland recognized Andrew’s generosity with the
Montgomery County William Donald Schaefer Helping People Award. A year later, he
was honored by the Foundation at the NIH with its Charles A. Sanders, MD, Partnership
Award for his “unwavering commitment to advancing biomedical research on rare
kidney cancers.”

Trailblazer
Though the advance of his cancer — coupled with the success of Driven To Cure,
which has raised more than $100,000 per year since its 2016 launch — meant Andrew
ultimately had to give up his studies at UNH, he’s had a lasting impact on Paul College.
The only sophomore among a group of seniors in Earle’s spring 2016 “Launching New
Ventures” class, his success with Driven To Cure was among the proof points that
helped the course earn a permanent spot in the curriculum; today, it’s the senior
capstone course for business students in the entrepreneurial studies option.
“That first class was essentially structured as a group of independent studies that all
met together,” recalls Earle, noting that the majority of his students came in with ideas in
the consumer products and high-tech realm. “Driven To Cure was the only nonprofit,
socially oriented initiative, and in that respect it provided a great template for what the
work coming out of the class could be and do. It’s become the most successful project
to come out of the class by far. Andrew really left a remarkable legacy.”
He’s also had a lasting impact at NIH. “I think it’s his humanity that touched us the
most,” says NIH Director Francis Collins, MD, who met Andrew when he made his first
DTC donation to the institute and became a friend thereafter. “He always had time to
share his story, to encourage another child or adult struggling with a frightening
diagnosis.” And of course, “He’d give thrills to the kids at The Children’s Inn at NIH
when he rumbled into the parking lot with his 700-horsepower GT-R.”
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In spring 2019, when it was clear that Andrew was running out of time, the Lee family
had some difficult decisions to make, including about whether Andrew would receive
hospice care at home or in the hospital. In part because he wanted to be able to donate

his living tissue for further research after his death, Andrew was admitted into the NIH’s
year-old hospice unit — among the early patients to make use of it.
In addition to the donation of his kidney tissue, which is critically important for
understanding HLRCC and its future treatment, Andrew allowed his hospice stay and
his final hours to be photographed, and those photos used by NIH for educational
purposes, training students in the pain and palliative care program. He also played a
role in the development of the NIH’s canine therapy program — with a little help from
Milo, the French bulldog he shared with longtime girlfriend Hailey Kellogg ’18, who
became the first dog to pay an inpatient visit to the NIH hospice unit. Because NIH is a
government agency (it’s a part of the U.S. Department of Health and Human Services),
Milo needed to get approved before he could be brought into the facility last year. “I
think he got cleared for access faster than the president of the United States,” Lee
laughs.
That Lee can laugh as he remembers his son’s final days is a tribute to his own
resilience, as well as the manner in which Andrew lived his life. At a June memorial
service attended by nearly 1,500 people whose lives he had touched, childhood friend
Michel Russo recalled Andrew’s “positivity, grit and selflessness in the midst of
adversity.” Joking that Andrew must have held a Maryland state record for the most
speeding tickets successfully avoided, Russo added, “but undebatable is the fact that
Andrew was always, always, destined for a life of influence. The cancer didn’t change
Andrew. It simply became the vehicle he used to share himself with the world.”
Proud
And then there’s Driven To Cure. Prior to Andrew’s death, the organization had received
donations from an already impressive 33 countries, but within five days of his passing,
that number swelled to a remarkable 160. Tributes poured in from the performance car
world and elsewhere; in December, the United States’ premier car show — the
Pennsylvania-based Carlisle Import and Performance Nationals — rebranded its May
2020 event as a memorial to Andrew, with proceeds bene- fitting DTC. Even now, Lee
notes, he continues to field emails and phone calls from people he’s never met whose
lives were touched by Andrew, and across the world, thousands of players of the
popular video car game Forza have built their own versions of Andrew’s GT-R in the
online platform — so many, that Driven To Cure is in talks with Forza about formalizing
a licensing agreement. (In fact, the image in the opening spread of this story is not
Andrew’s actual GT-R but a virtual ver- sion of the DTC car, built by a European Forza
gamer.) “He’s become known globally for the work that he did to raise awareness for
HLRCC and other rare kidney cancers,” Lee says. “That’s pretty incredible.”

BRUCE LEE WITH LILY COCKRUM AT NIH.
Bittersweet as the reason for that recognition may be, Lee says DTC’s future is
extremely bright. For now, it remains a grassroots operation, staffed by the Lee family
and a handful of volunteers — which means nearly every dollar raised goes to research
and not to operating costs. In late 2019, the organization expanded its financial support
to include UCLA, where Brian Shuch, MD, one of Andrew’s doctors from Yale and NIH
now heads up rare kidney cancer research; Lee presented the program with a check for
$102,000 in January. Andrew’s GT-R, the expenses for which the Lee family covers
privately, will be back on the road in the spring, following some much-needed
reconditioning. Andrew may be gone, but his story — and that of Driven To Cure — is
still unfolding. As Andrew himself said upon accepting NIH’s Charles Sanders
Partnership award in 2018, “Driven To Cure is not about me. It’s about the road ahead
and a lot of people making it possible for those after me to face better odds, even a
cure, through biomedical research.”
Indeed, the road that Andrew envisioned is already becoming a reality. In January, Lily
Cockrum, the 8-year- old from North Carolina who was at risk for HLRCC, traveled to
NIH for several days of medical testing. Having helped facilitate introductions and Lily’s
appointments with members of NIH’s HLRCC clinical team, Bruce Lee was on hand to
support Lily and her mother, Dawn, and was among the first to hear the good news: The
spot on Lily’s kidney that local doctors had suspected was an HLRCC tumor is a benign
cyst. Because she has the FH mutation, however, Lily remains at risk for HLRCC, and
she will now be monitored regularly by NIH — the youngest patient to enter its HLRCC
protocol. If she does develop the disease, it will be caught almost immediately.

Lee would certainly be forgiven if he were to voice a little wistfulness about the
Cockrums’ good fortune relative to his family’s own. But the word that he uses when he
shares the story is proud. “Andrew’s goal was to raise awareness so people could
diagnose and catch HLRCC early,” he says. “Driven To Cure is doing that.”
To learn more about the organization Andrew Lee ’18 started at UNH with his dream car
and a devastating diagnosis, visit driventocure.org.
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